SCHEMBL750562

SCHEMBL750562

CC(=O)c1ccc(Cl)c(Cl)c1Br

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
NOTUM Q6P988 3/20 0.37
TSHR P16473 2/20 0.36
MAPK1 P28482 3/20 0.33
CYP3A4 P08684 2/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CLCN2 P51788 1/20 0.33
RAB9A P51151 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CXCR1 P25024 1/20 0.33
CXCR2 P25025 1/20 0.33
HPGD P15428 1/20 0.32
TP53 P04637 1/20 0.32
CASP1 P29466 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5696491 0.85 ALDH1A1 (0.39) ALDH1A1TSHRMAPK1CYP3A4KMT2A
SCHEMBL11658669 0.83 ALDH1A1 (0.38) ALDH1A1NOTUMTSHRMAPK1CYP3A4
SCHEMBL8997789 0.81 TSHR (0.52) ALDH1A1TSHRKMT2ASMN1; SMN2CLCN2
SCHEMBL30610932 0.80 CYP3A4 (0.42) ALDH1A1NOTUMTSHRMAPK1CYP3A4
SCHEMBL403103 0.80 CYP3A4 (0.42) ALDH1A1NOTUMTSHRMAPK1CYP3A4
SCHEMBL30343106 0.80 HPGD (0.41) ALDH1A1NOTUMKMT2AATMSMN1; SMN2
SCHEMBL478785 0.80 HPGD (0.41) ALDH1A1NOTUMKMT2AATMSMN1; SMN2
SCHEMBL8751491 0.79 KMT2A (0.50) ALDH1A1TSHRKMT2AATMCLCN2
SCHEMBL19810438 0.79 ABL1 (0.46) ALDH1A1TSHRKMT2AATMSMN1; SMN2
SCHEMBL27537296 0.79 HSP90AB1 (0.42) ALDH1A1TSHRMAPK1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2429295-B1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF ALBANY MOLECULAR RES INC (US) 2013-12-25 EP disclosed
EP-2429295-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF Albany Molecular Research, Inc. (US) 2012-03-21 EP disclosed
WO-2010132437-A1 ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2010-11-18 WO disclosed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 ALDH1A1 3209/4885NOTUM 976/4885TSHR 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.